Miss. House debate stalls PBM transparency conference report after point of order

The Mississippi House of Representatives spent more than an hour debating a conference report tied to legislation intended to increase transparency around pharmacy benefit managers (PBMs) and to give independent pharmacies more rights to appeal reimbursement decisions.

Supporters described the package as a set of “sunshine” and consumer-protection measures intended to track rebates and require detailed reporting to the Board of Pharmacy; critics warned the measure had limits and that some important issues — notably rebate accounting — remained unresolved.

A House sponsor, speaking at length during the report explanation, said the bill would require PBMs and PSAOs (pharmacy services administrative organizations) to publish annual reports to the Board of Pharmacy, disclose ownership ties with pharmacies, prohibit spread pricing, and create an administrative appeals process for reimbursement disputes. The sponsor said the Board would publish non‑proprietary information on a public website and that the bill includes a three‑year repealer with an effective date of July 1, 2025.

“Section 6 also requires PBMs to disclose the plan sponsor or the employer's rebate money. One hundred percent of the rebate money has to be disclosed under section 6,” the sponsor said during the explanation (excerpted from the meeting transcript). That same speaker also acknowledged the measure does not resolve every concern: “Do I hope this bill reduces the cost of drugs to your constituents back home? Yes. I pray that it does. Will it? Honestly, I don't know.”

Several members pressed whether the bill addressed so‑called clawbacks, whether independent pharmacists supported the package and whether the legislation would actually lower retail drug costs. Representative Lydia Curry of Lincoln County told colleagues she sees patients who “skip days of insulin because they can't afford to pay for it,” and said she wished the legislation went further to reduce out‑of‑pocket costs.

During later floor debate, Representative Clark of Holmes raised a procedural point of order, asserting the conference report contained new code sections that were not part of the original House bill. The chair sustained the point of order under Joint Rule 25, and the presiding officer announced the effect: the conference report was to be returned to conference.

Because the point of order was sustained, the measure will not be finally adopted by the House at this time; conferees must reconvene to reconcile the House and Senate language before the bill can be brought back to the floor.

Why it matters: The legislation tackles several technical components of PBM oversight — appellate rights for pharmacists, audit authority for the Board of Pharmacy, ownership and rebate disclosure, and prohibitions on steering and spread pricing. Supporters argued the bill restores elements from earlier House efforts to force transparency in drug pricing; opponents and skeptical members said the conference report still leaves rebate flows and ultimate consumer impacts unresolved.

The immediate procedural outcome — a point of order sustained under Joint Rule 25 — sends the conference report back to conferees for further negotiation rather than to a final House vote.

What’s next: Conferees will need to correct the procedural defects the point of order identified and reconcile the House and Senate versions. The sponsor said some issues (notably physician UPL and other complex payment matters referenced elsewhere in the session) will be studied further and addressed in future bills if needed.